EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma
โ Scribed by Futamura, Naohisa; Nishida, Yoshihiro; Urakawa, Hiroshi; Kozawa, Eiji; Ikuta, Kunihiro; Hamada, Shunsuke; Ishiguro, Naoki
- Book ID
- 121561897
- Publisher
- S. Karger AG
- Year
- 2014
- Tongue
- English
- Weight
- 491 KB
- Volume
- 35
- Category
- Article
- ISSN
- 1010-4283
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## BACKGROUND. It has been reported that the c-erbB-2 protooncogene is frequently amplified and overexpressed in many types of cancers, except sarcomas and hematological malignancies. METHODS. Expression of ErbB-2 in the tumors of 26 patients with conventiional osteosarcoma was evaluated by immuno
Matrix metalloproteinase 2 (MMP-2) plays a crucial role in invasion and metastasis of malignant tumors. Membrane type 1-MMP (MT1-MMP) was originally identified as an activator of MMP-2. Tissue inhibitor of MMP-2 (TIMP-2) was identified as an inhibitor of MMP-2 and MT1-MMP. However, TIMP-2 was report
The matrix metalloproteinases (MMPs) are a family of closely related proteolytic enzymes which are involved in the degradation of different components of the extracellular matrix. There is increasing evidence to indicate that individual MMPs have an important role in tumour invasion and tumour sprea